{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:06:30Z","timestamp":1787889990756,"version":"build-2784847793"},"reference-count":84,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>There is an urgent need for targeted and effective COVID\u201019 treatments. Several medications, including hydroxychloroquine, remdesivir, lopinavir\u2013ritonavir, favipiravir, tocilizumab and others have been identified as potential treatments for COVID\u201019. Bringing these repurposed medications to the public for COVID\u201019 requires robust and high\u2010quality clinical trials that must be conducted under extremely challenging pandemic conditions. This article reviews translational science principles and strategies for conducting clinical trials in a pandemic and evaluates recent trials for different drug candidates. We hope that this knowledge will help focus efforts during this crisis and lead to the expedited development and approval of COVID\u201019 therapies.<\/jats:p>","DOI":"10.1111\/bcp.14629","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T14:23:14Z","timestamp":1603981394000},"page":"2170-2185","source":"Crossref","is-referenced-by-count":17,"title":["Challenges of drug development during the COVID\u201019 pandemic: Key considerations for clinical trial designs"],"prefix":"10.1111","volume":"87","author":[{"given":"Jun","family":"Shi","sequence":"first","affiliation":[{"name":"dMed  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Xiao","sequence":"additional","affiliation":[{"name":"dMed  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Zhang","sequence":"additional","affiliation":[{"name":"dMed  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghao","family":"Geng","sequence":"additional","affiliation":[{"name":"dMed  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Cong","sequence":"additional","affiliation":[{"name":"dMed  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin X.","family":"Shi","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine Northwestern University  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Knapp","sequence":"additional","affiliation":[{"name":"Sanofi (retired)  Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-01315-7"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25748"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.03.006"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00272"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320879"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_2_7_8_1","unstructured":"ChenZW HuJJ ZhangZW et al.Efficacy of hydroxychloroquine in patients with COVID\u201019: results of a randomized clinical trial. medRxiv.2020."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1764871"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa623"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4742"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510062"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.748"},{"key":"e_1_2_7_16_1","unstructured":"World Health Organization & World Health Organization. (2020).Report of the who\u2010china joint mission on coronavirus disease 2019 (covid\u201019). Available on\u2010line:https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report.pdf"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180"},{"issue":"6","key":"e_1_2_7_18_1","first-page":"13","article-title":"Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS\u2010Coronavirus\u20102 in Shenzhen. China","volume":"68","author":"Wang Y","year":"2020","journal-title":"J Infect Dis"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2001899"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6913e1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"issue":"18","key":"e_1_2_7_22_1","first-page":"1775","article-title":"Case\u2010fatality rate and characteristics of patients dying in relation to COVID\u201019 in Italy","volume":"323","author":"Onder G","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004911117"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.031"},{"key":"e_1_2_7_27_1","first-page":"1","article-title":"Venous thromboembolism complicated with COVID\u201019: what do we know so far?","author":"Tal S","year":"2020","journal-title":"Acta Haematol"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6912e2"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600279"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111967"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104742"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2002589117"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461"},{"issue":"10237","key":"e_1_2_7_34_1","first-page":"1607","article-title":"COVID\u201019 and angiotensin\u2010converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","volume":"395","author":"Patel AB","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31094-1"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0695-z"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30141-9"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511812"},{"issue":"4","key":"e_1_2_7_39_1","first-page":"309","article-title":"Treatment of severe acute respiratory syndrome with convalescent plasma","volume":"9","author":"Burnouf T","year":"2003","journal-title":"Hong Kong Med J"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25707"},{"key":"e_1_2_7_42_1","doi-asserted-by":"crossref","unstructured":"WangK ChenW ZhouYS et al.SARS\u2010CoV\u20102 invades host cells via a novel route: CD147\u2010spike protein. bioRxiv.2020.","DOI":"10.1101\/2020.03.14.988345"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.02.026"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9"},{"key":"e_1_2_7_45_1","article-title":"Increasing host cellular receptor\u2010angiotensin\u2010converting enzyme 2 expression by coronavirus may facilitate 2019\u2010nCoV (or SARS\u2010CoV\u20102) infection","author":"Zhuang MW","year":"2020","journal-title":"J Med Virol"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2011.02.020"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchem.1961"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp9001969"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0156-0"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.03.005"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.03.011"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12797"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922083117"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00459-8"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/v12040372"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv100"},{"key":"e_1_2_7_65_1","unstructured":"Coronavirus (COVID\u201019) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047"},{"issue":"3","key":"e_1_2_7_67_1","first-page":"185","article-title":"Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia","volume":"43","author":"Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia","year":"2020","journal-title":"Zhonghua Jie he he Hu Xi Za Zhi"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30287-5"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-020-09930-x"},{"key":"e_1_2_7_70_1","first-page":"369","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"1849","author":"Tang W","year":"2020","journal-title":"BMJ"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016638"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001191"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_2_7_75_1","unstructured":"Gilead announces results from phase 3 trial of remdesivir in patients with moderate COVID\u201019 https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/6\/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19"},{"key":"e_1_2_7_76_1","unstructured":"Gilead announces results from phase 3 trial of investigational antiviral remdesivir in patients with severe COVID\u201019 https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/4\/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19."},{"key":"e_1_2_7_77_1","doi-asserted-by":"crossref","unstructured":"WHO SOLIDARITY Trial Consortium PanH PetoR KarimQA et al.Repurposed antiviral drugs for COVID\u201019; interim WHO SOLIDARITY trial results. medRxiv 2020.https:\/\/doi.org\/10.1101\/2020.10.15.20209817","DOI":"10.1101\/2020.10.15.20209817"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.2003.012658"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30196-1"},{"issue":"8","key":"e_1_2_7_82_1","first-page":"907","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"Madelain V","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"18","key":"e_1_2_7_83_1","article-title":"Experimental treatment with favipiravir for COVID\u201019: an open\u2010label control study","author":"Cai Q","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"e_1_2_7_85_1","unstructured":"Regeneron and Sanofi provide update on KEVZARA\u00ae (Sarilumab) phase 3 U.S. Trial in COVID\u201019 patients.https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:18:49Z","timestamp":1693588729000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/bcp.14629"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14629","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]}}}